Scarica l'app Stockscreener
0.00
100.00%
-41.03
Dopo l'orario di chiusura:
41.06
41.06
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$41.03
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$5.25B
Reddito:
$1.11B
Utile/perdita netta:
$133.27M
Rapporto P/E:
0.00
EPS:
1.0006
Flusso di cassa netto:
$37.47M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$41.14
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
0.00 | 5.25B | 1.11B | 133.27M | 37.47M | 1.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-13 | Iniziato | Roth Capital | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2026-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS Suspended by Cantor Fitzgerald -- Rating Remains Neutral - GuruFocus
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals - BioPharm International
Biogen upgraded to Hold after Apellis acquisition boosts prospects despite challenges. - Pluang
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins - TechStock²
Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) - Stock Titan
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - Yahoo Finance
Biogen Completes Acquisition of Apellis Pharmaceuticals - Sahm
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen Acquires Apellis Pharmaceuticals (APLS) to Enhance Growth Potential - GuruFocus
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Biogen–Apellis (APLS) deal triggers GC’s cash, CVR and option changes - Stock Titan
Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders - Stock Titan
Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Biogen (APLS counterparty) closes Apellis tender offer and merger with cash and CVR deal - Stock Titan
Biogen stock (US09062X1037): closes $5.3B Apellis deal - AD HOC NEWS
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over - TechStock²
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):